迈克生物(300463.SZ)拟设立参股公司 推动“国家精准医学产业创新中心”建设和运营
格隆汇12月3日丨迈克生物(300463.SZ)公布,公司于2019年12月02日与成都利康实业有限责任公司(系四川大学华西医院全资子公司)、上海医药集团股份有限公司、成都高新投资集团有限公司、成都科技服务集团有限公司、四川希氏异构医疗科技有限公司、成都华西海圻医药科技有限公司签署了《成都华西精准医学产业创新中心有限公司出资人协议书》(“《出资人协议书》”),拟在成都市高新区共建“国家精准医学产业创新中心”,并共同出资设立成都华西精准医学产业创新中心有限公司(“合资公司”)运营该中心。合资公司注册资本5亿元,迈克生物占合资公司注册资本的10%。合资公司已于2019年12月2日取得成都高新技术产业开发区市场监督管理局颁发的营业执照。
成都华西精准医学产业创新中心有限公司经营范围:生物技术、医药技术(不含医疗卫生活动)、基因工程技术、细胞工程技术、医疗器械、人工智能技术、计算机技术研究、技术推广、技术转让、技术咨询、技术服务;医学研究和试验发展;其他技术推广服务;科技中介服务。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
公司此次参与投资设立的合资公司,将借助四川大学华西医院的科研技术和广泛医疗资源,股东单位发挥各自资源、人才和技术等优势,推动“国家精准医学产业创新中心”的建设和运营。精准医学产业涵盖分子诊断、细胞治疗、靶向药物、医学人工智能、生物医学材料、创新医疗器械等多平台,此次投资将有助于公司对标国际前沿技术方向,促进公司在分子诊断平台的技术创新和成果转移转化,为公司布局精准医疗领域的战略规划建立良好的基础。
通过此次投资,公司将参与到精准医学产业链上中下游的资源整合中,可以增强产学研合作和临床资源获取,加快研发成果转化和产业化进程,对公司未来发展产生积极作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.